Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 known ✓ | O43570 | 3/20 | 0.71 |
| ▸ | CA1 known ✓ | P00915 | 3/20 | 0.71 |
| ▸ | CA2 known ✓ | P00918 | 3/20 | 0.71 |
| ▸ | CA4 known ✓ | P22748 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 3/20 | 0.71 |
| ▸ | CA9 | Q16790 | 3/20 | 0.71 |
| ▸ | MAOB | P27338 | 7/20 | 0.57 |
| ▸ | APP | P05067 | 1/20 | 0.57 |
| ▸ | PTPRZ1 | P23471 | 1/20 | 0.57 |
| ▸ | AR | P10275 | 1/20 | 0.56 |
| ▸ | MMP1 | P03956 | 1/20 | 0.56 |
| ▸ | MMP2 | P08253 | 1/20 | 0.56 |
| ▸ | MMP9 | P14780 | 1/20 | 0.56 |
| ▸ | MMP14 | P50281 | 1/20 | 0.56 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.56 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.55 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.54 |
| ▸ | RORC | P51449 | 1/20 | 0.50 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.49 |
| ▸ | CA5A | P35218 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5443121 | 0.83 | CA12 (0.71) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1462243 | 0.83 | CA12 (0.70) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6949461 | 0.82 | CA12 (0.69) | CA12CA1CA2CA7CA9 | |
| SCHEMBL27550091 | 0.82 | MAOB (0.80) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7857590 | 0.78 | SOS1 (0.66) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1306434 | 0.78 | MMP2 (0.50) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL22662767 | 0.77 | AR (0.64) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5606537 | 0.77 | MAOB (0.67) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4051544 | 0.77 | CA12 (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL18937890 | 0.76 | MAOB (0.71) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1181286-B1 | 3-(ARYLSULFONYLAMINO)-TETRAHYDROPYRAN-3-CARBOXYLIC ACID HYDROXAMIDES | PFIZER PROD INC (US) | 2003-11-12 | — | — | EP | disclosed |
| EP-1181285-B1 | 3-(ARYLSULFONYLAMINO)-TETRAHYDROFURAN-3-CARBOXYLIC ACID HYDROXAMIDES | PFIZER PROD INC (US) | 2003-10-08 | — | — | EP | disclosed |
| EP-0977733-B1 | ARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES | PFIZER PROD INC (US) | 2003-09-03 | — | — | EP | disclosed |
| US-6599890-B1 | Inhibitors of matrix metalloproteinases or the production of tumor necrosis factor | PFIZER INC | 2003-07-29 | — | — | US | disclosed |
| EP-1070058-B1 | (4-ARYLSULFONYLAMINO)-TETRAHYDROPYRAN-4-CARBOXYLIC ACID HYDROXAMIDES | PFIZER PROD INC (US) | 2003-05-02 | — | — | EP | disclosed |
| EP-1181286-A1 | 3-(ARYLSULFONYLAMINO)-TETRAHYDROPYRAN-3-CARBOXYLIC ACID HYDROXAMIDES | Pfizer Products Inc. (US) | 2002-02-27 | — | — | EP | disclosed |
| EP-1181285-A2 | 3-(ARYLSULFONYLAMINO)-TETRAHYDROFURAN-3-CARBOXYLIC ACID HYDROXAMIDES | Pfizer Products Inc. (US) | 2002-02-27 | — | — | EP | disclosed |
| US-6342521-B1 | DRUGS FOR TREATMENT OF ARTHRITIS | PFIZER INC. | 2002-01-29 | — | — | US | disclosed |
| US-20020006920-A1 | Arylsulfonylamino hydroxamic acid derivatives | ROBINSON RALPH PELTON (US) | 2002-01-17 | — | — | US | disclosed |
| US-6303636-B1 | FOR THERAPY OF ARTHRITIS, CANCER, TISSUE ULCERATION, RESTENOSIS, PERIODONTAL DISEASE, EPIDERMOLYSIS BULLOSA, SCIERITIS, SEPSIS, SEPTIC SHOCK AND OTHER DISEASES INVOLVING THE PRODUCTION OF TUMOR NECROSIS FACTOR | PFIZER INC | 2001-10-16 | — | — | US | disclosed |
| US-6197810-B1 | ANTIARTHRITIC AGENTS; ANTICANCE RAGENTS; ANTIINFLAMMATORY AGENTS | PFIZER INC | 2001-03-06 | — | — | US | disclosed |
| EP-1070058-A1 | (4-ARYLSULFONYLAMINO)-TETRAHYDROPYRAN-4-CARBOXYLIC ACID HYDROXAMIDES | Pfizer Products Inc. (US) | 2001-01-24 | — | — | EP | disclosed |
| WO-2000073295-A1 | 3-(ARYLSULFONYLAMINO)-TETRAHYDROPYRAN-3-CARBOXYLIC ACID HYDROXAMIDES | PFIZER PRODUCTS INC. (US) | 2000-12-07 | — | — | WO | disclosed |
| WO-2000073294-A2 | 3-(ARYLSULFONYLAMINO)-TETRAHYDROFURAN-3-CARBOXYLIC ACID HYDROXAMIDES | PFIZER PRODUCTS INC. (US) | 2000-12-07 | — | — | WO | disclosed |
| US-6087392-A | A METALLOPROTEINASE INHIBITORS FOR INHIBITING MAMMALIAN REPROLYSIN | PFIZER INC. (US) | 2000-07-11 | — | — | US | disclosed |
| EP-0977733-A1 | ARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES | Pfizer Products Inc. (US) | 2000-02-09 | — | — | EP | disclosed |
| EP-0960098-A1 | ARYLSULFONYL HYDROXAMIC ACID DERIVATIVES | PFIZER INC. (US) | 1999-12-01 | — | — | EP | disclosed |
| WO-1999052889-A1 | (4-ARYLSULFONYLAMINO)-TETRAHYDROPYRAN-4-CARBOXYLIC ACID HYDROXAMIDES | PFIZER PRODUCTS INC. (US) | 1999-10-21 | — | — | WO | disclosed |
| WO-1998034918-A1 | ARYLSULFONYL HYDROXAMIC ACID DERIVATIVES | PFIZER INC. (US) | 1998-08-13 | — | — | WO | disclosed |
| WO-1998033768-A1 | ARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1998-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006920-A1 | Arylsulfonylamino hydroxamic acid derivatives | MMP8, MMP1, MMP10 | CA12 3958/4885CA1 2612/4885CA2 2445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.